Место кандесартана в современной кардиологии

1. Гиляревский С.Р. Современные возможности блокады ренин- ангиотензиновой системы: остаются ли ингибиторы ангиотензинпревращающего фермента препаратами первого ряда? Consilium Medicum. 2010; 12 (5): 18–23. / Gilyarevsky SR. Modern possibilities of blockade of the renin-angiotensin system: stay whether ACE inhibitors first-line drugs? Consilium Mediсum. 2010; 12 (5): 18–23. [in Russian]
2. Остроумова О.Д., Хорьков С.А., Копченов И.И. Возможности антагонистов рецепторов к ангиотензину II в органопротекции у больных с артериальной гипертонией. Consilium Mediсum. 2009; 11 (5): 29–37. / Ostroumova OD, Khorkov SA, Kopchenov II. Features receptor antagonists of angiotensin II in the organo in patients with hypertension. Consilium Mediсum. 2009; 11 (5): 29–37. [in Russian]
3. Смирнова Е.А., Лиферов Р.А., Якушин С.С. Распространенность и оценка эффективности медикаментозной терапии артериальной гипертонии в Рязанской области. Рос. мед.-биол. вестн. им. академика И.П.Павлова 2008; 4: 73–79. / Smirnova E.A., Liferov R.A., Iakushin S.S. Rasprostranennost i otsenka effektivnosti medikamentoznoi terapii arterialnoi gipertonii v Riazanskoi oblasti. Ros. med.-biol. vestn. im. akademika I.P.Pavlova 2008; 4: 73–79. [in Russian]
4. Захарова Н.В., Кузьмина-Крутецкая С.Р. Клиническая фармакология сартанов: класс-эффект и фармакодинамические особенности препаратов. Системные гипертензии. 2011; 8 (3): 12–7. / Zakharova NV, Kuzmina-Krutetskayaа SR. Clinical pharmacology sartans: their class-effect and pharmacodynamics features. Systemic Hypertension. 2011; 8 (3): 12–7. [in Russian]
5. Добрынина Н.В. Что мы знаем о кандесартане: возможности клинического применения. Consilium Mediсum. 2016; 5: 67–9. / Dobrynina N. What do we know about candesartane: clinical applications. Consilium Mediсum. 2016; 5: 67–9. [in Russian]
6. Abrahamsson Т, Karp L, Brabdl-Eliasson II el al. Candesartan causes long-last antagonism of angiotensin II receptor-mediated contractile effects in isolated vascular preparations: a comparison with irbesartan, losartan and its active metabolite (EXP-3174). Blood Pressure 2000; 9: 1–52.
7. Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation 2001; 103: 904–12.
8. Евдокимова А.Г., Ложкина М.В., Коваленко Е.В. Особенности применения кандесартана в клинической практике. Consilium Mediсum. 2016; 18 (1): 68–73. / Evdokimova AG, Lozhkina MV, Kovalenko EV. Key features of candesartan application in clinical practice. Consilium Mediсum. 2016; 18 (1): 68–73. [in Russian]
9. Остроумова О.Д., Бондарец О.В., Гусева Т.Ф. Преимущества кандесартана в лечении артериальной гипертонии. Системные гипертензии. 2014; 11 (2): 42–6. / Ostroumova OD, Bondarec OV, Guseva TF. The benefits of candesartan usage in the treatment of arterial hypertension. Systemic Hypertension. 2014; 11 (2): 42–6. [in Russian]
10. Клиническая фармакология. Под ред. В.Г.Кукеса. 4-е изд. М.: ГЭОТАР-Медиа, 2008: с. 392–6. / Klinicheskaia farmakologiia. Pod red. V.G.Kukesa. 4-e izd. M.: GEOTAR-Media, 2008: s. 392–6. [in Russian]
11. Морозова Т.Е. Сартаны в лечении больных артериальной гипертензией высокого риска: возможности кандесартана. Системные гипертензии. 2013; 10 (2): 34–9. / Morozova TE. Sartans in the treatment of patients with arterial hypertension at high risk: the possibility of candesartan. Systemic Hypertension. 2013; 10 (2): 34–9. [in Russian]
12. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Доказательная история кандесартана: прошлое, будущее и настоящее. Сердечная недостаточность. 2015; 16 (5): 303–10. / Giliarevskii S.R., Golshmid M.V., Kuz'mina I.M. Dokazatel'naia istoriia kandesartana: proshloe, budushchee i nastoiashchee. Serdechnaia nedostatochnost'. 2015; 16 (5): 303–10. [in Russian]
13. Israili ZH. Clinical of angiotensin II (AT I) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): 73–86.
14. Oparll S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 pt 2): 188–248.
15. Le MT, De Bakcer JP, Hanyady L et al. Ligand binding and functional properties of human angiotensin AT I receptors in transiently and stably expressed CHO-K1 cell. Eur J Pharmacol 2005; 513 (1–2): 35–45.
16. Van Liefde, Vauquelin G. Sartan AT receptorinteractions: evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302 (2): 237.
17. Кравченко Е.В. Врачу-практику: место кандесартана (Кандесартан – НАН) в современной терапии артериальной гипертензии. Cardiology in Belarus 2016; 8 (2): 286–95. / Kravchenko E.V. Vrachu-praktiku: mesto kandesartana (Kandesartan – NAN) v sovremennoi terapii arterial'noi gipertenzii. Cardiology in Belarus 2016; 8 (2): 286–95. 
[in Russian]
18. Minatogucbi S, Aoyama T, Kawai N et al. Comparative effect candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and beart rate. Blood Press 2013; 22.
19. Weisser B, Gerwe M, Funken C. Investigation of the antihypertensive long – term action of candesartan cilexetil in different dosadges under the influence therapy – free intervals. Arzneimittelforschung 2005; 55 (9): 501–13.
20. Кобалава Ж.Д, Склизкова Л.А., Тарапата Н.П. Обоснование, опыт и перспектива применения кандесартана цилексетила. Клин. фармакология и терапия. 2001; 1: 92–6. / Kobalava Zh.D, Sklizkova L.A., Tarapata N.P. Obosnovanie, opyt i perspektiva primeneniia kandesartana tsileksetila. Klin. farmakologiia i terapiia. 2001; 1: 92–6. [in Russian]
21. Zheng Z, Shi H, Jia J. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. Journal of the Renin-Angiotensin-Aldosterone System 2011; 12 (3): 365–74.
22. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenteral, randomized, active treatment- controlled, parallel grope, efficacy and tolerability of candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011; 33 (8): 1043–56.
23. Easthope SE, Jarvis B. Candesartan cilexetil in update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
24. Bakris G, Gradman A, Reif M et al. and the CLAIM Study Investigators. Antihypertensive efficacy of candesartanin comparison to losartan: the CLAIM Study. J Clin Hypertens 2001; 3: 16–21.
25. Vidi DG, While WB, Ridley E et al. and the CLAIM Study Investigators. A forsed titration study of antihypertensive efficacy of candesartanin cilexetil in comparison to losartan. CLAIM Study II. J Hum Hypertens 2001; 15: 475–80. 
26. Hasegawa H, Takano H, Kameda E et al. Effect of swiching from telmisartan, valsartan, olmesartan or losartan, to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
27. Escobar C, Barrios V, Calderon A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008; 10: 208–14.
28. Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009; 11: 35–41.
29. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
30. Недогода С.В., Саласюк А.С., Барыкина И.М. и др. Особенности антигипертензивной терапии. Мед. совет. 2014; 17: 42–9. / Nedogoda S.V., Salasiuk A.S., Barykina I.M. i dr. Osobennosti antigipertenzivnoi terapii. Med. sovet. 2014; 17: 42–9. [in Russian]
31. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
32. De Rosa MJ. Angiotensin II receptor blockers and cardioprotection. Vasc Health Risk Manag 2010; 6: 1047–63.
33. Burgess E, Muirhead N, Rene de Cotret P et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893–900.
34. Yusuf S, Pfeffer MA, Swedberg K et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
35. Щулькин А.В., Филимонова А.А., Трунина Т.П. Фармакотерапия артериальной гипертензии у пациентов на гемодиализе. Наука молодых. 2016; 3: 28–34. / Shchul'kin A.V., Filimonova A.A., Trunina T.P. Farmakoterapiia arterial'noi gipertenzii u patsientov na gemodialize. Nauka molodykh. 2016; 3: 28–34. [in Russian]
36. Бубнова М.Г. Прикладные аспекты клинического применения. Мед. совет. 2014; 12: 70–8. / Bubnova M.G. Prikladnye aspekty klinicheskogo primeneniia. Med. sovet. 2014; 12: 70–8. [in Russian]
37. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92.
38. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
39. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1203–12.
40. Suzuki T, Nozawa T, Fujii N et al. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Coron Artery Dis 2011; 22: 352–35.
41. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. и др. «Новейшая история» лекарственной терапии больных артериальной гипертонией: только ли антигипертензивная терапия? Consilium Mediсum. 2016; 8 (5): 36–42. / Gilyarevskyi RS, Goldshmid MV, Kuzmina IM et al. «The recent history» of drug therapy of patients with arterial hypertension: is it only antihypertensive therapy? Consilium Mediсum. 2016; 18 (5): 36–42. [in Russian]
42. Отчет о клиническом исследовании CNDN-01. Открытое, рандомизированное, перекрестное исследование сравнительной фармакокинетики и биоэквивалентности препаратов Гипосарт, таблетки 32 мг, Фармацевтический завод «Польфарма» АО (Польша), и Атаканд®, таблетки 32 мг, «АстраЗенека АБ» (Швеция), с участием здоровых добровольцев. М., 2013. / Otchet o klinicheskom issledovanii CNDN-01. Otkrytoe, randomizirovannoe, perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Giposart, tabletki 32 mg, Farmatsevticheskii zavod «Pol'farma» AO (Pol'sha), i Atakand®, tabletki 32 mg, «AstraZeneka AB» (Shvetsiia), s uchastiem zdorovykh dobrovol'tsev. M., 2013. [in Russian]

________________________________________________

1. Gilyarevsky SR. Modern possibilities of blockade of the renin-angiotensin system: stay whether ACE inhibitors first-line drugs? Consilium Mediсum. 2010; 12 (5): 18–23. [in Russian]
2. Ostroumova OD, Khorkov SA, Kopchenov II. Features receptor antagonists of angiotensin II in the organo in patients with hypertension. Consilium Mediсum. 2009; 11 (5): 29–37. [in Russian]
3. Smirnova E.A., Liferov R.A., Iakushin S.S. Rasprostranennost i otsenka effektivnosti medikamentoznoi terapii arterialnoi gipertonii v Riazanskoi oblasti. Ros. med.-biol. vestn. im. akademika I.P.Pavlova 2008; 4: 73–79. [in Russian]
4. Zakharova NV, Kuzmina-Krutetskayaа SR. Clinical pharmacology sartans: their class-effect and pharmacodynamics features. Systemic Hypertension. 2011; 8 (3): 12–7. [in Russian]
5. Dobrynina N. What do we know about candesartane: clinical applications. Consilium Mediсum. 2016; 5: 67–9. [in Russian]
6. Abrahamsson Т, Karp L, Brabdl-Eliasson II el al. Candesartan causes long-last antagonism of angiotensin II receptor-mediated contractile effects in isolated vascular preparations: a comparison with irbesartan, losartan and its active metabolite (EXP-3174). Blood Pressure 2000; 9: 1–52.
7. Burnier M. Angiotensin II Type 1 Receptor Blockers. Circulation 2001; 103: 904–12.
8. Evdokimova AG, Lozhkina MV, Kovalenko EV. Key features of candesartan application in clinical practice. Consilium Mediсum. 2016; 18 (1): 68–73. [in Russian]
9. Ostroumova OD, Bondarec OV, Guseva TF. The benefits of candesartan usage in the treatment of arterial hypertension. Systemic Hypertension. 2014; 11 (2): 42–6. [in Russian]
10. Klinicheskaia farmakologiia. Pod red. V.G.Kukesa. 4-e izd. M.: GEOTAR-Media, 2008: s. 392–6. [in Russian]
11. Morozova TE. Sartans in the treatment of patients with arterial hypertension at high risk: the possibility of candesartan. Systemic Hypertension. 2013; 10 (2): 34–9. [in Russian]
12. Giliarevskii S.R., Golshmid M.V., Kuz'mina I.M. Dokazatel'naia istoriia kandesartana: proshloe, budushchee i nastoiashchee. Serdechnaia nedostatochnost'. 2015; 16 (5): 303–10. [in Russian]
13. Israili ZH. Clinical of angiotensin II (AT I) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): 73–86.
14. Oparll S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 pt 2): 188–248.
15. Le MT, De Bakcer JP, Hanyady L et al. Ligand binding and functional properties of human angiotensin AT I receptors in transiently and stably expressed CHO-K1 cell. Eur J Pharmacol 2005; 513 (1–2): 35–45.
16. Van Liefde, Vauquelin G. Sartan AT receptorinteractions: evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302 (2): 237.
17. Kravchenko E.V. Vrachu-praktiku: mesto kandesartana (Kandesartan – NAN) v sovremennoi terapii arterial'noi gipertenzii. Cardiology in Belarus 2016; 8 (2): 286–95. 
[in Russian]
18. Minatogucbi S, Aoyama T, Kawai N et al. Comparative effect candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and beart rate. Blood Press 2013; 22.
19. Weisser B, Gerwe M, Funken C. Investigation of the antihypertensive long – term action of candesartan cilexetil in different dosadges under the influence therapy – free intervals. Arzneimittelforschung 2005; 55 (9): 501–13.
20. Kobalava Zh.D, Sklizkova L.A., Tarapata N.P. Obosnovanie, opyt i perspektiva primeneniia kandesartana tsileksetila. Klin. farmakologiia i terapiia. 2001; 1: 92–6. [in Russian]
21. Zheng Z, Shi H, Jia J. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. Journal of the Renin-Angiotensin-Aldosterone System 2011; 12 (3): 365–74.
22. Lee HY, Hong BK, Chung WJ et al. Phase IV, 8-week, multicenteral, randomized, active treatment- controlled, parallel grope, efficacy and tolerability of candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension. Clin Ther 2011; 33 (8): 1043–56.
23. Easthope SE, Jarvis B. Candesartan cilexetil in update of its use in essential hypertension. Drugs 2002; 62: 1253–87.
24. Bakris G, Gradman A, Reif M et al. and the CLAIM Study Investigators. Antihypertensive efficacy of candesartanin comparison to losartan: the CLAIM Study. J Clin Hypertens 2001; 3: 16–21.
25. Vidi DG, While WB, Ridley E et al. and the CLAIM Study Investigators. A forsed titration study of antihypertensive efficacy of candesartanin cilexetil in comparison to losartan. CLAIM Study II. J Hum Hypertens 2001; 15: 475–80. 
26. Hasegawa H, Takano H, Kameda E et al. Effect of swiching from telmisartan, valsartan, olmesartan or losartan, to candesartan on morning hypertension. Clin Exp Hypertens 2012; 34 (2): 86–91.
27. Escobar C, Barrios V, Calderon A et al. Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) 2008; 10: 208–14.
28. Penicka M, Gregor P, Kerekes R et al. Candesartan use in Hypertrophic And Non-obstructive Cardiomyopathy Estate (CHANCE) Study. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009; 11: 35–41.
29. Lithell H, Hansson L, Skoog I et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
30. Nedogoda S.V., Salasiuk A.S., Barykina I.M. i dr. Osobennosti antigipertenzivnoi terapii. Med. sovet. 2014; 17: 42–9. [in Russian]
31. Kasanuki H, Hagiwara N, Hosoda S et al. HIJ-CREATE Investigators. Angiotensin II receptor blockerbased vs. nonangiotensin II receptor blockerbased therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
32. De Rosa MJ. Angiotensin II receptor blockers and cardioprotection. Vasc Health Risk Manag 2010; 6: 1047–63.
33. Burgess E, Muirhead N, Rene de Cotret P et al. SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893–900.
34. Yusuf S, Pfeffer MA, Swedberg K et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–81.
35. Shchul'kin A.V., Filimonova A.A., Trunina T.P. Farmakoterapiia arterial'noi gipertenzii u patsientov na gemodialize. Nauka molodykh. 2016; 3: 28–34. [in Russian]
36. Bubnova M.G. Prikladnye aspekty klinicheskogo primeneniia. Med. sovet. 2014; 12: 70–8. [in Russian]
37. Ducharme A, Swedberg K, Pfeffer MA et al. CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92.
38. Ogihara T, Fujimoto A, Nakao K, Saruta T. CASE-J Trial Group. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. Exp Rev Cardiovasc Ther 2008; 6 (9): 1195–201.
39. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30 (10): 1203–12.
40. Suzuki T, Nozawa T, Fujii N et al. Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Coron Artery Dis 2011; 22: 352–35.
41.Gilyarevskyi RS, Goldshmid MV, Kuzmina IM et al. «The recent history» of drug therapy of patients with arterial hypertension: is it only antihypertensive therapy? Consilium Mediсum. 2016; 18 (5): 36–42. [in Russian]
42. Otchet o klinicheskom issledovanii CNDN-01. Otkrytoe, randomizirovannoe, perekrestnoe issledovanie sravnitel'noi farmakokinetiki i bioekvivalentnosti preparatov Giposart, tabletki 32 mg, Farmatsevticheskii zavod «Pol'farma» AO (Pol'sha), i Atakand®, tabletki 32 mg, «AstraZeneka AB» (Shvetsiia), s uchastiem zdorovykh dobrovol'tsev. M., 2013. [in Russian]

Н.В.Добрынина

ФГБОУ ВО «Рязанский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России. 390026, Россия, Рязань, ул. Высоковольтная, д. 7
lec.roccd@gmail.com

________________________________________________